Skip to main
  1. Stocks
  2. Nkarta, Inc.
  3. Forecast
NKTX

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta is well positioned because NKX019 is showing early efficacy in autoimmune disease that appears comparable to CAR-T benchmarks, with 83% of IIM patients and 86% of SSc patients achieving meaningful responses at the 4B cell dose. The safety profile is a major differentiator, as across 40 AID patients no CRS, ICANS, IEC-HS, or GvHD were observed, supporting the potential for outpatient use and broader adoption. Fundamentally, the company also has a scalable off-the-shelf NK-cell platform, a deep pipeline opportunity in large U.S. markets, and management’s plan to optimize dosing up to 6B cells while targeting launch in 2031.

Bears say

Nkarta is a clinical-stage company with all of its programs still in Phase I, leaving its pipeline highly exposed to clinical failure, weak efficacy, or insufficient durability, and there is no assurance it can produce additional successful candidates from its NK cell platform or Crispr collaboration. Its commercial case is further weakened by intense competition in IIM and SSc, while no NK cell therapies have been approved by the FDA or EMA to date, creating substantial regulatory uncertainty and a long path to market with no guarantee of share capture. Financially, the company is likely to need additional funding to advance trials and eventual launch, and the risk of unfavorable financing, dilution, manufacturing setbacks, and a modeled 30% probability of success for NKX019 underscores a fragile risk-reward profile.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction

Get the latest Nkarta, Inc. (NKTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nkarta, Inc. (NKTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction

Get the latest Nkarta, Inc. (NKTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nkarta, Inc. (NKTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NKTX stock data and trends